Orodispersible tablets for pediatric drug delivery: current challenges and recent advances

References

• Bellis JR, Kirkham JJ, Nunn AJ, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital [Article]. Br J Clin Pharmacol. 2014;77(3):545–553.
   PubMed Web of Science ®Google Scholar
• Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use and amending, Regulation (EEC) No 1768/92, Directive.
   Google Scholar
• Food and Drug Administration regulatory information: food and Drug Administration Safety and Innovation Act (FDASIA) Accessed 2017 Sept 15. www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/default.htm
   Google Scholar
• European Medicines Agency (EMA). Guideline on pharmaceutical development of medicines for paediatric use (2013), EMA/CHMP/QWP/805880/2012 Rev. 2.
   Google Scholar
• Ernest TB, Elder DP, Martini LG, et al. Developing paediatric medicines: identifying the needs and recognizing the challenges [Review]. J Pharm Pharmacol. 2007;59(8):1043–1055.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - Drug disposition, action, and therapy in infants and children [Review]. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Breitkreutz J, Boos J. Paediatric and geriatric drug delivery [Review]. Expert Opin Drug Deliv. 2007;4(1):37–45.
   PubMed Web of Science ®Google Scholar
• ICH Topic E 11: clinical Investigation of Medicinal Products in the Paediatric Population: note for guidance on clinical investigation of medicinal products in the paediatric population (2001). International Conference on Harmonisation, adopted by EMA (CPMP/ICH/2711/99).
   Google Scholar
• European Medicines Agency (EMA). Reflection Paper: formulations of choice for the paediatric population (2006), EMEA/CHMP/PEG/194810/2005.
   Google Scholar
• Walsh J, Cram A, Woertz K, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients [Review]. Adv Drug Deliv Rev. 2014;73:14–33.
   PubMed Web of Science ®Google Scholar
• Klingmann V. Acceptability of Mini-Tablets in Young Children: results from Three Prospective Cross-over Studies [Review]. AAPS PharmSciTech. 2017;18(2):263–266.
   PubMed Web of Science ®Google Scholar
• Preis M. Orally Disintegrating Films and Mini-Tablets—Innovative Dosage Forms of Choice for Pediatric Use [Review]. AAPS PharmSciTech. 2015;16(2):234–241.
   PubMed Web of Science ®Google Scholar
• Orlu M, Ranmal SR, Sheng Y, et al. Acceptability of orodispersible films for delivery of medicines to infants and preschool children [Article]. Drug Deliv. 2017;24(1):1243–1248.
   PubMed Web of Science ®Google Scholar
• Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - A novel solid oral dosage form for paediatric use [Article]. Eur J Pharm Biopharm. 2011;78(3):462–469.
   PubMed Web of Science ®Google Scholar
• Hoppu K. Time to change the paradigm of children’s medicines from liquid formulations to flexible solid oral dosage forms [Editorial]. Ceylon Med J. 2016;61(3):93–95.
   PubMed Web of Science ®Google Scholar
• World Health Organisation (WHO) EB. Working document QAS/08.257/Rev.1, Development of paediatric medicines: points to consider in formulation, 2010, Available from: https://www.who.int/medicines/services/expertcommittees/pharmprep/Rev2-PaediatricMedicinesDevelopment_QAS08-257Rev1_8102010.pdf ( last access 2021 Nov 05).
   Google Scholar
• European Pharmacopoeia Commission. Tablets. In European Pharmacopoeia. 10.0 edition. European Directorate for the Quality of Medicines (EDQM); Strasbourg, France; 2019. 01 2018: 0478.
   Google Scholar
• Guidance for Industry - Orally Disintegrating Tablets, U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD, USA.
   Google Scholar
• Medicines for Malaria Venture - Coartem® Dispersible Facts, https://www.mmv.org/access/products-projects/coartem-dispersible-acute-uncomplicated-malaria-children, accessed on 2021 Jun 22nd.
   Google Scholar
• Seager H. Drug-delivery Products and the Zydis Fast-dissolving Dosage Form. J Pharm Pharmacol. 1998;50(4):375–382.
   PubMed Web of Science ®Google Scholar
• Wehling F, Schuehle S, Madamala N, Effervescent dosage form with microparticles, US Patent 5178878A, assigned to Cima Labs, Inc., Eden Prairie, MN, USA, Jan 12, 1993.
   Google Scholar
• Wehling F, Schuehle S, Base coated acid particles and effervescent formulation incorporating same, US Patent 5503846A, assigned to Cima Labs, Inc., Eden Prairie, MN, USA, June 06, 1993.
   Google Scholar
• Khankari RK, Hontz J, Chastain SJ, et al., Rapidly dissolving robust dosage form, US Patent US6024981A, assigned to Cima Labs, Inc., Eden Prairie, MN, USA, Feb 15, 2000.
   Google Scholar
• Mizumoto T, Masuda Y, Kajiyama A, et al., US Patent 6589554B1, Tablets quickly disintegrating in the oral cavity and process for producing the same, assigned to Yamanouchi Pharmaceutical Co Ltd, Yamanouchi Pharma Technologies Inc, Jul 08, 2003.
   Google Scholar
• Mizumoto T, Masuda Y, Fukui M, Intrabuccally dissolving compressed moldings and production process thereof, US Patent 5576014A, assigned to Yamanouchi Pharmaceutical Co Ltd, Yamanouchi Pharma Technologies Inc, Nov19, 1996.
   Google Scholar
• Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies [Article]. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–475.
   PubMed Web of Science ®Google Scholar
• Zhou H, Herron J, Liu Y, et al. A new rapidly disintegrating formulation of cisapride is bioequivalent to standard cisapride tablets in the elderly [Article]. Clin Drug Invest. 1997;14(6):487–493.
   Web of Science ®Google Scholar
• Yapar E. Orally disintegrating tablets: an overview. J Appl Pharm Sci, 2014;4(2):118–125. 02/01
   Google Scholar
• Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly [Review]. Eur J Pharm Sci. 2015;75:2–9.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Drugs@FDA database: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm, accessed on 2021 Apr 30th.
   Google Scholar
• Al-Khattawi A, Mohammed AR. Compressed orally disintegrating tablets: excipients evolution and formulation strategies [Review]. Expert Opin Drug Deliv. 2013;10(5):651–663.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Koizumi KI, Zama Y, et al. New Compressed Tablet Rapidly Disintegrating in Saliva in the Mouth Using Crystalline Cellulose and a Disintegrant [Article]. Biol Pharm Bull. 1995;18(9):1308–1310.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Mukai B, Shiraishi S, et al. Preparation of Rapidly Disintegrating Tablet Using New Types of Microcrystalline Cellulose (PH-M Series) and Low Substituted-Hydroxypropylcellulose or Spherical Sugar Granules by Direct Compression Method. Chem Pharm Bull. 2001;49(2):134–139.
   PubMed Web of Science ®Google Scholar
• Yoshinari T, Forbes RT, York P, et al. Moisture induced polymorphic transition of mannitol and its morphological transformation. Int J Pharm. 2002;247(1):69–77. 2002/10/24/
   PubMedGoogle Scholar
• Ali A-K, Ahmad A, Yvonne P, et al. Multi Stage Strategy to Reduce Friability of Directly Compressed Orally Disintegrating Tablets. Drug Deliv Lett. 2012;2(3):195–201.
   Google Scholar
• Ilkka J, Paronen P. Prediction of the compression behaviour of powder mixtures by the Heckel equation. Int J Pharm. 1993;94(1):181–187. 1993/06/21/
   Google Scholar
• Bowles BJ, Dziemidowicz K, Lopez FL, et al. Co-Processed Excipients for Dispersible Tablets–Part 1: manufacturability [Article]. AAPS PharmSciTech. 2018;19(6):2598–2609.
   PubMed Web of Science ®Google Scholar
• Pich CH, Moest T, Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten. EU Patent EP 0166 315 B1, August 08, 1989.
   Google Scholar
• Lennartz P, Mielck JB. Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm. 1998;173(1):75–85. 1998/10/30/
   Google Scholar
• Soulairol I, Chaheen M, Tarlier N, et al. Evaluation of disintegrants functionality for orodispersible mini tablets [Article]. Drug Dev Ind Pharm. 2017;43(11):1770–1779.
   PubMed Web of Science ®Google Scholar
• Soulairol I, Sanchez-Ballester NM, Aubert A, et al. Evaluation of the super disintegrant functionalities of alginic acid and calcium alginate for the design of orodispersible mini tablets [Article]. Carbohydr Polym. 2018;197:576–585.
   PubMed Web of Science ®Google Scholar
• El-Say KM, Ahmed TA, Abdelbary MF, et al. Risperidone oral disintegrating mini-tablets: a robust-product for pediatrics [Article]. Acta Pharm. 2015;65(4):365–382.
   PubMed Web of Science ®Google Scholar
• Ortega CA, Favier LS, Cianchino VA, et al. New orodispersible mini tablets of enalapril maleate by direct compression for pediatric patients [Article]. Curr Drug Deliv. 2020;17(6):505–510.
   PubMed Web of Science ®Google Scholar
• Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan, EMEA-001706-PIP01-14-M02, European Medicine Agency, London, October 19, 2018.
   Google Scholar
• Labeling of Enalapril from Neonates up to Adolescents, European Commission Information Sheet, Ref. Number 110066, [cited 2021 Jul 08]. Available from: https://cordis.europa.eu/project/id/602295/de. 2021.
   Google Scholar
• EuropeanMedicinesAgency. Decision on the acceptance of a modification of an agreed paediatric investigation plan for enalapril (maleate) (EMEA-001706-PIP01-14-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. 2018.
   Google Scholar
• West TG, Bradbury TJ 3D Printing: a Case of ZipDose® Technology – world’s First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product. 3D and 4D Printing in Biomedical Applications 2019. p. 53–79.
   Google Scholar
• Katstra WE, Palazzolo RD, Rowe CW, et al. Oral dosage forms fabricated by Three Dimensional Printing(TM) [Article]. J Control Release. 2000;66(1):1–9.
   PubMed Web of Science ®Google Scholar
• Rowe CW, Katstra WE, Palazzolo RD, et al. Multimechanism oral dosage forms fabricated by three dimensional printing(TM) [Article]. J Control Release. 2000;66(1):11–17.
   PubMed Web of Science ®Google Scholar
• Wu BM, Borland SW, Giordano RA, et al. Solid free-form fabrication of drug delivery devices [Article]. J Control Release. 1996;40(1–2):77–87.
   Web of Science ®Google Scholar
• Full Presciribing Information for Spritam, Reference ID 4733186, Aprecia Pharmaceuticals, LLC, Blue Ash, OH 45242, 01/2021.
   Google Scholar
• Fina F, Madla CM, Goyanes A, et al. Fabricating 3D printed orally disintegrating printlets using selective laser sintering [Article]. Int J Pharm. 2018;541(1–2):101–107.
   PubMed Web of Science ®Google Scholar
• Shi K, Tan DK, Nokhodchi A, et al. Drop-On-Powder 3D printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil [Article]. Pharmaceutics. 2019;11:4.
   Web of Science ®Google Scholar
• Infanger S, Haemmerli A, Iliev S, et al. Powder bed 3D-printing of highly loaded drug delivery devices with hydroxypropyl cellulose as solid binder [Article]. Int J Pharm. 2019;555:198–206.
   PubMedGoogle Scholar
• El Aita I, Breitkreutz J, Quodbach J. On-demand manufacturing of immediate release levetiracetam tablets using pressure-assisted microsyringe printing [Article]. Eur J Pharm Biopharm. 2019;134:29–36.
   PubMed Web of Science ®Google Scholar
• Childress A, Newcorn J, Stark JG, et al. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder [Article]. J Child Adolesc Psychopharmacol. 2016;26(6):505–512.
   PubMed Web of Science ®Google Scholar
• Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting [Article]. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.
   PubMed Web of Science ®Google Scholar
• Stark JG, Engelking D, McMahen R, et al. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/hyperactivity disorder [Article]. J Child Adolesc Psychopharmacol. 2017;27(3):216–222.
   PubMed Web of Science ®Google Scholar
• Marraffino A, Sikes CR, Laage T, et al. An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children [Article]. J Child Adolesc Psychopharmacol. 2020;30(1):15–20.
   PubMed Web of Science ®Google Scholar
• Fraser IP, Han L, Han TH, et al. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study [Article]. Headache. 2012;52(4):625–635.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Pearlman E, Hämäläinen M, et al. Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs [Article]. Headache. 2013;53(1):104–117.
   PubMed Web of Science ®Google Scholar
• **Emeryk A, Vallet T, Wawryk-Gawda E, et al. Acceptability of a sublingual drug formulation for respiratory tract infections in children aged 3 to 5 years [Article]. Pharmaceutics. 2021;13(2):1–12.
   Web of Science ®Google Scholar
• **Wagner-Hattler L, Kiene K, Bielicki J, et al. High Acceptability of an Orally Dispersible Tablet Formulation by Children. Children. 2021;8:3.
   Google Scholar
• Ruiz F, Vallet T, Pensé-Lhéritier AM, et al. Standardized method to assess medicines’ acceptability: focus on paediatric population [Article]. J Pharm Pharmacol. 2017;69(4):406–416.
   PubMed Web of Science ®Google Scholar
• Alyami H, Dahmash E, Alyami F, et al. Dosage form preference consultation study in children and young adults: paving the way for patient-centred and patient-informed dosage form development [Article]. Eur J Hosp Pharm. 2017;24(6):332–337.
   PubMedGoogle Scholar
• Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study [Article]. Int J Pharm. 2016;514(1):296–307.
   PubMedGoogle Scholar
• Alyami H, Koner J, Huynh C, et al. Current opinions and recommendations of paediatric healthcare professionals – the importance of tablets: emerging orally disintegrating versus traditional tablets [Article]. PLoS ONE. 2018;13:2.
   Web of Science ®Google Scholar
• Rautamo M, Kvarnström K, Sivén M, et al. A focus group study about oral drug administration practices at hospital wards—aspects to consider in drug development of age-appropriate formulations for children [Article]. Pharmaceutics. 2020;12:2.
   Web of Science ®Google Scholar
• Gebrauchsinformation: information für den Anwender - Nurofen Schmelztabletten Lemon 200 mg; Reckitt Benckiser Deutschland GmbH, 69115 Heidelberg, Germany, last revised 07/2018.
   Google Scholar
• Saito J, Akabane M, Komura M, et al. Age-Appropriate Pediatric Dosage Forms in Japan: insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation [Article]. Therapeutic Innovation and Regulatory Science. 2019;53(4): 455–471
   PubMed Web of Science ®Google Scholar
• Thomson SA, Tuleu C, Wong ICK, et al. Minitablets: new modality to deliver medicines to preschool-aged children [Article]. Pediatrics. 2009;123(2):e235–e238.
   PubMed Web of Science ®Google Scholar
• Klingmann V, Seitz A, Meer T, et al. Acceptability of Uncoated Mini-Tablets in Neonates—A Randomized Controlled Trial [Article]. J Paediatr. 2015;167(4):893–896.e2.
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges [Review]. Adv Drug Deliv Rev. 2014;73:102–126.
   PubMed Web of Science ®Google Scholar
• *Münch J, Meer T, Mayatepek E, et al. Acceptability of Small-Sized Oblong tablets in Comparison to Syrup and Mini-tablets in Infants and Toddlers: a Randomized Controlled Trial. Eur J Pharm Biopharm. 2021;166:126–134.
   PubMed Web of Science ®Google Scholar
• Temer AC, Teixeira MT, Sa-Barreto LL, et al. Subdivision of Tablets Containing Modified Delivery Technology: the Case of Orally Disintegrating Tablets [Article]. J Pharm Innov. 2018;13(3):261–269.
   Web of Science ®Google Scholar
• Kayitare E, Vervaet C, Ntawukulilyayo JD, et al. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications [Article]. Int J Pharm. 2009;370(1–2):41–46.
   PubMed Web of Science ®Google Scholar
• Haraguchi T, Miyazaki A, Yoshida M, et al. Bitterness evaluation of intact and crushed Vesicare orally disintegrating tablets using taste sensors [Article]. J Pharm Pharmacol. 2013;65(7):980–987.
   PubMed Web of Science ®Google Scholar
• Thabet Y, Walsh J, Breitkreutz J. Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets [Article]. Int J Pharm. 2018;541(1–2):136–142.
   PubMedGoogle Scholar
• Tolia V, Han C, North JD, et al. Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children [Article]. Clin Drug Investig. 2005;25(5):285–292.
   PubMed Web of Science ®Google Scholar
• Tokuyama E, Matsunaga C, Yoshida K, et al. Famotidine orally disintegrating tablets: bitterness comparison of original and generic products [Article]. Chem Pharm Bull. 2009;57(4):382–387.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Siddiqui A, Khan MA. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation [Article]. Eur J Pharm Biopharm. 2013;85(3PART B):1300–1309.
   PubMedGoogle Scholar
• Soliman II, Kandil SM, Abdou EM. Gabapentin–saccharin co-crystals with enhanced physicochemical properties and in vivo absorption formulated as oro-dispersible tablets [Article]. Pharm Dev Technol. 2020;25(2):227–236.
   PubMed Web of Science ®Google Scholar
• Wang C, Hu S, Sun CC. Expedited development of a high dose orally disintegrating metformin tablet enabled by sweet salt formation with acesulfame [Article]. Int J Pharm. 2017;532(1):435–443.
   PubMedGoogle Scholar
• Labib GS. Novel levocetirizine HCl tablets with enhanced palatability: synergistic effect of combining taste modifiers and effervescence technique [Article]. Drug Des Devel Ther. 2015;9:5135–5146.
   PubMed Web of Science ®Google Scholar
• Matsui R, Uchida S, Namiki N. Combination effect of physical and gustatory taste masking for propiverine hydrochloride orally disintegrating tablets on palatability [Article]. Biol Pharm Bull. 2015;38(1):17–22.
   PubMed Web of Science ®Google Scholar
• Takano H, Uchida S, Kashiwagura Y, et al. Preparation of cocoa powder-containing orally disintegrating tablets of rebamipide (rebamipide chocolet) and evaluation of their clinical palatability [Article]. Chem Pharm Bull. 2019;67(2):112–119.
   PubMed Web of Science ®Google Scholar
• Sotoyama M, Uchida S, Tanaka S, et al. Citric acid suppresses the bitter taste of olopatadine hydrochloride orally disintegrating tablets [Article]. Biol Pharm Bull. 2017;40(4):451–457.
   PubMed Web of Science ®Google Scholar
• Rachid O, Rawas-Qalaji M, Simons KJ. Epinephrine in anaphylaxis: preclinical study of pharmacokinetics after sublingual administration of taste-masked tablets for potential pediatric use [Article]. Pharmaceutics. 2018;10:1.
   Web of Science ®Google Scholar
• Dziemidowicz K, Lopez FL, Bowles BJ, et al. Co-Processed Excipients for Dispersible Tablets—Part 2: patient Acceptability [Article]. AAPS PharmSciTech. 2018;19(6):2646–2657.
   PubMed Web of Science ®Google Scholar
• Kalra A, Bhat P, Kaur IP. Deciphering molecular mechanics in the taste masking ability of Maltodextrin: developing pediatric formulation of Oseltamivir for viral pandemia [Article]. Carbohydr Polym. 2021 260 ;117703.
   PubMedGoogle Scholar
• Shukla D, Chakraborty S, Singh S, et al. Fabrication and evaluation of taste masked resinate of risperidone and its orally disintegrating tablets [Article]. Chem Pharm Bull. 2009;57(4):337–345.
   PubMed Web of Science ®Google Scholar
• Tawakkul MA, Shah RB, Zidan A, et al. Complexation of risperidone with a taste-masking resin: novel application of near infra-red and chemical imaging to evaluate complexes [Article]. Pharm Dev Technol. 2009;14(4):409–421.
   PubMed Web of Science ®Google Scholar
• Basu B, Aviya KR, Bhattacharya A. Development and characterization of mouth dissolving tablets of prednisolone [Article]. J Pharm Invest. 2014;44(2):79–102.
   Google Scholar
• Chandrasekaran P, Kandasamy R. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform [Article]. AAPS PharmSciTech. 2017;18(6):1972–1986.
   PubMed Web of Science ®Google Scholar
• Musuc AM, Anuta V, Atkinson I, et al. Development and characterization of orally disintegrating tablets containing a captopril-cyclodextrin complex [Article]. Pharmaceutics. 2020;12(8):1–18.
   Web of Science ®Google Scholar
• Jang DJ, Bae SK, Oh E. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients [Article]. Biomed Pharmacother. 2014;68(8):1117–1124.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Uchida S, Sugiura T, et al. The prediction of the palatability of orally disintegrating tablets by an electronic gustatory system [Article]. Int J Pharm. 2015;493(1–2):305–312.
   PubMedGoogle Scholar
• Choudhary N, Avari J. Formulation and evaluation of taste mask pellets of granisetron hydrochloride as oro dispersible tablet [Article]. Braz J Pharm Sci. 2015;51(3):569–578.
   Web of Science ®Google Scholar
• Cantor SL, Khan MA, Gupta A. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride [Article]. Drug Dev Ind Pharm. 2015;41(7):1156–1164.
   PubMed Web of Science ®Google Scholar
• Wagner KG, Krumme M, Schmidt PC. Investigation of the pellet-distribution in single tablets via image analysis [Article]. Eur J Pharm Biopharm. 1999;47(1):79–85.
   PubMed Web of Science ®Google Scholar
• Wagner KG, Krumme M, Schmidt PC. Pellet-containing tablets examination of distribution and deformation behaviour [Article]. STP Pharm Sci. 2000;10(4):327–334.
   Google Scholar
• Guhmann M, Preis M, Gerber F, et al. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations [Article]. Drug Dev Ind Pharm. 2015;41(4):540–551.
   PubMed Web of Science ®Google Scholar
• Drašković M, Medarević D, Aleksić I, et al. In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets [Article]. Drug Dev Ind Pharm. 2017;43(5):723–731.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tasaki H, Maeda A, et al. Mechanism of controlled drug release from a salting-out taste-masking system. J Control Release. 2008;131(1):47–53. 2008/10/06/
   PubMed Web of Science ®Google Scholar
• Astellas Launches Orally Disintegrating Tablet “Vesicare® OD” in Japan, https://www.astellas.com/system/files/news/2018-06/110420_Eg.pdf, accessed on 2021 Jul 8th.
   Google Scholar
• Lou H, Liu M, Qu W, et al. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics [Article]. Drug Dev Ind Pharm. 2014;40(7):910–918.
   PubMed Web of Science ®Google Scholar
• Xu J, Bovet LL, Zhao K. Taste masking microspheres for orally disintegrating tablets [Article]. Int J Pharm. 2008;359(1–2):63–69.
   PubMed Web of Science ®Google Scholar
• Tung NT, Tran CS, Nguyen TL, et al. Formulation and biopharmaceutical evaluation of bitter taste masking microparticles containing azithromycin loaded in dispersible tablets [Article]. Eur J Pharm Biopharm. 2018;126:187–200.
   PubMed Web of Science ®Google Scholar
• Lopalco A, Denora N, Laquintana V, et al. Taste masking of propranolol hydrochloride by microbeads of EUDRAGIT® E PO obtained with prilling technique for paediatric oral administration [Article]. Int J Pharm. 2020 574 ;118922.
   PubMedGoogle Scholar
• *Deng Y, Shen L, Yang Y, et al. Development of nanoparticle-based orodispersible palatable pediatric formulations [Article]. Int J Pharm. 2021 596 ;120206.
   PubMedGoogle Scholar
• Yıldız S, Aytekin E, Yavuz B, et al. Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules [Article]. Pharm Dev Technol. 2018;23(5):488–495.
   PubMed Web of Science ®Google Scholar
• Tan Q, Zhang L, Liu G, et al. Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: design rationale and evaluation [Article]. Drug Dev Ind Pharm. 2013;39(9):1364–1371.
   PubMed Web of Science ®Google Scholar
• Petrovick GF, Kleinebudde P, Breitkreutz J. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: influence of process parameters on tablet properties [Article]. Eur J Pharm Biopharm. 2018;122:137–145.
   PubMed Web of Science ®Google Scholar
• Yıldız S, Aytekin E, Yavuz B, et al. Formulation studies for mirtazapine orally disintegrating tablets [Article]. Drug Dev Ind Pharm. 2016;42(6):1008–1017.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran P, Kandasamy R. Development of Extended-Release Oral Flexible Tablet (ER-OFT) Formulation for Pediatric and Geriatric Compliance: an Age-Appropriate Formulation [Article]. AAPS PharmSciTech. 2017;18(7):2394–2409.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: the Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability [Article]. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 1995;12(3): 413–420
   Google Scholar
• Buckley ST, Frank KJ, Fricker G, et al. Biopharmaceutical classification of poorly soluble drugs with respect to “enabling formulations.” Eur J Pharm Sci. 2013;50(1):8–16. 2013/09/27/
   PubMed Web of Science ®Google Scholar
• Baghel S, Cathcart H, O’Reilly NJ. Polymeric Amorphous Solid Dispersions: a Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs [Review]. J Pharm Sci. 2016;105(9):2527–2544.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development [Review]. Pharmacol Rev. 2013;65(1):315–499.
   PubMed Web of Science ®Google Scholar
• Refaat A, Sokar M, Ismail F, et al. Tadalafil oral disintegrating tablets: an approach to enhance tadalafil dissolution [Article]. J Pharm Invest. 2015;45(5):481–491.
   Google Scholar
• Mohamed MS, Abdelhafez WA, Zayed G, et al. In vitro and in vivo characterization of fast dissolving tablets containing gliquidone–pluronic solid dispersion [Article]. Drug Dev Ind Pharm. 2019;45(12):1973–1981.
   PubMed Web of Science ®Google Scholar
• Szabó P, Sebe I, Stiedl B, et al. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement [Article]. J Pharm Biomed Anal. 2015;115:359–367.
   PubMed Web of Science ®Google Scholar
• Chen YD, Liang ZY, Cen YY, et al. Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma [Article]. Drug Des Devel Ther. 2015;9:5815–5825.
   PubMedGoogle Scholar
• Anup N, Thakkar S, Misra M. Formulation of olanzapine nanosuspension based orally disintegrating tablets (ODT); comparative evaluation of lyophilization and electrospraying process as solidification techniques [Article]. Adv Powder Technol. 2018;29(8):1913–1924.
   Web of Science ®Google Scholar
• Conceição J, Adeoye O, Cabral-Marques H, et al. Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients [Article]. AAPS PharmSciTech. 2020;21:2.
   Web of Science ®Google Scholar
• de Freitas Neto JL, Idn GB, de Melo CG, et al. Development of pediatric orodispersible tablets based on efavirenz as a new therapeutic alternative [Article]. Curr HIV Res. 2020;18(5):342–353.
   PubMed Web of Science ®Google Scholar
• Zeng F, Wang L, Zhang W, et al. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes [Article]. AAPS PharmSciTech. 2013;14(2):854–860.
   PubMed Web of Science ®Google Scholar
• Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children [Article]. J Acquired Immune Deficiency Syndromes. 2011;58(4):385–391.
   PubMed Web of Science ®Google Scholar
• Koziolek M, Grimm M, Becker D, et al. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap® System. J Pharm Sci. 2015;104(9):2855–2863. 2015/09/01/
   PubMed Web of Science ®Google Scholar
• Trasi NS, Purohit HS, Taylor LS. Evaluation of the Crystallization Tendency of Commercially Available Amorphous Tacrolimus Formulations Exposed to Different Stress Conditions [Article]. Pharm Res. 2017;34(10):2142–2155.
   PubMed Web of Science ®Google Scholar
• Moqbel HA, ElMeshad AN, El-Nabarawi MA. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation [Article]. Drug Deliv. 2016;23(8):2998–3007.
   PubMed Web of Science ®Google Scholar
• Package leaflet: Information for the user - Kaletra (80 mg + 20 mg)/ml oral solution; AbbVie Ltd, Maidenhead, UK, last revised 03/2021, last revised 03/2021; [cited 2021 May 31]. Available from: https://www.medicines.org.uk/emc/files/pil.1315.pdf
   Google Scholar
• Sosnik A, Seremeta KP, Imperiale JC, et al. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases [Review]. Expert Opin Drug Deliv. 2012;9(3):303–323.
   PubMed Web of Science ®Google Scholar
• Package leaflet: information for the user - Sporanox 10 ml/ml oral solution; Janssen-Cilag Ltd, High Wycombe, UK, last revised 05/2021; [cited 2021 Jun 17]. Available from: https://www.medicines.org.uk/emc/files/pil.1522.pdf.
   Google Scholar
• Patil HG, Tiwari RV, Repka MA, et al. Formulation and development of orodispersible sustained release tablet of domperidone [Article]. Drug Dev Ind Pharm. 2016;42(6):906–915.
   PubMed Web of Science ®Google Scholar
• Tromp AK. Multipartikuläre Minitabletten. Duesseldorf: Heinrich Heine University Duesseldorf; 2019.
   Google Scholar
• Shimizu T, Sugaya M, Nakano Y, et al. Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets [Article]. Chemical and Pharmaceutical Bulletin. 2003;51(10): 1121–1127
   PubMed Web of Science ®Google Scholar
• Baldi F, Malfertheiner P. Lansoprazole Fast Disintegrating Tablet: a New Formulation for an Established Proton Pump Inhibitor. Digestion. 2003;67(1–2):1–5.
   PubMed Web of Science ®Google Scholar
• Full Presciribing Information for Prevacid (lansoprazole) delayed-release capsules for oral use and Prevacid Solutab (lansoprazole) delayed-release orally disintegrating tablets, Reference ID 4707944, Takeda Pharmaceuticals America, Inc., Lexington, MA, 11/2020.
   Google Scholar
• Therapeutics N, FORM 10-K for the fiscal year ended December 31, 2017 to the United States Securities and Exchange Commission, Commission File Number 001-36292. [cited 2021 Jun 30]. Available from: https://www.sec.gov/Archives/edgar/data/1467652/000104746918001730/a2234488z10-k.htm.
   Google Scholar
• Tengler M, McMahen R, Compositions and methods of making rapidly dissolving ionically masked formulations, US Patent 8,840,924 B2, assigned to NEOS Therapeutics, LP, Grand Prairie, TX, USA, Sep. 23, 2014.
   Google Scholar
• Full Prescribing Information for Adzenys XR-ODT, Reference ID 4036384, Neos Therapeutics, LP., Grand Prairie, TX 75050, 01/2016.
   Google Scholar
• Full Presciribing Information for Cotempla XR-ODT, Reference ID 4113408, Neos Therapeutics, LP., Grand Prairie, TX 75050, 06/2017.
   Google Scholar